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Abstract
Background: Obesity is a well-known condition of resistant hypertension (HT). Insights to the hemodynamic
patterns that characterize obesity related hypertension may help guide therapeutic adjustments and shorten time
to HT control.
Methods: We performed a retrospective analysis of 202 patients followed at our Hypertension Clinic with the
diagnosis of primary HT and who performed an impedance cardiography (ICG) test. Obtained data was analyzed to
identify differences between obese and non-obese patients and to identify predictors of uncontrolled HT (≥ 140
and/or ≥ 90 mmHg) in obese patients.
Results: One hundred patients were male (49.5%) and average age 54.6 ± 13.9 years. Average systolic and diastolic
pressures were 136.5 ± 22.4 mmHg and 82.9 ± 5.1 mmHg, respectively. The average BMI was 28.9 ± 5.1 Kg/m2. Seventy
one patients (35.1%) had systolic arterial pressure (AP) ≥140 mmHg and 45 patients (22.3%) diastolic AP ≥90 mmHg.
BMI correlated with systolic and diastolic AP (Pearson’s coefficient 0.235; p < 0.001 and 0.163; p < 0.001, respectively).
Obese patients presented increased cardiac index (CI) (p < 0.001), left cardiac work index (LCWI) (p < 0.001) and
systemic vascular resistance index (SVRI) (p < 0.001) but reduced systemic arterial compliance index (SACI) (p < 0.001).
Obese patients with uncontrolled HT had greater BMI (p < 0.001), CI (p < 0.001) and SVRI (p < 0.001) but lower SACI (p
< 0.001) and LCWI (p < 0.001). In multivariate analysis, however, only CI remained predictive, conferring a risk 1.47
higher of uncontrolled HT.
Conclusions: Obese patients, including those with uncontrolled HT, had increased CI and SVRI. The only predictor of
uncontrolled HT, however, was CI, suggesting that the obese present a state of hyperinotropy and may benefit of
“add-on” or increase treatment with beta-blockers.
Keywords: Obesity, Hypertension, Impedance cardiography, Body mass index, Cardiac index, Systemic vascular
resistance index
Background
The complex interplay between obesity and hyperten-
sion has been a matter of interest and debate for a long
time. In the last decade several new insights into the
pathophysiology linking obesity and hypertension have
led to a better understanding of the mechanisms that
beneath this association: insulin resistance, activation of
the renin-angiotensin-aldosterone system (RAAS), dys-
functional adipose tissue and deregulated synthesis of
adipokines, increased activity of the sympathetic nervous
system, overproduction of inflammatory cytokines and
obstructive sleep apnea are among some of these factors
[1]. Together, these neuro-endocrine imbalances contrib-
ute to vascular and endothelial dysfunction, impaired
pressure natriuresis and sodium excretion, increased
cardiac output and changes in systemic vascular resist-
ance and arterial compliance [2]. In this respect, the
measurement of hemodynamic parameters may be a
valuable tool for the management of obese hypertensive
patients, not only to identify the main abnormalities
associated with elevated blood pressure (increased CI,
SVRI or fluid volume) [3] but also to help guide
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therapeutic adjustments according to the spectrum of
hemodynamic changes identified [4].
It is also worthwhile to note that obesity is one of the
most frequent causes of resistant hypertension, and
identification of major hemodynamic abnormalities may
help shorten the time to achieve blood pressure control
and reduce global cardiovascular risk [3].
While invasive procedures are not adequate for ambu-
latory patients, non-invasive monitoring may be easily
implemented using accurate and reproducible tech-
niques like impedance cardiography [5]. Previous studies
have shown the value of this technique in tailoring
hypertension treatment in individual patients [6] and
several trials have used ICG in large cohorts of hyper-
tensive’s to identify factors associated with resistant
hypertension [7] or to better achieve blood pressure
control in patients with uncontrolled hypertension [3, 8].
We aimed to identify hemodynamic variables associated
with poor blood pressure control in a population of
obese hypertensive patients using ICG and to categorize
the main changes in hemodynamic parameters associ-
ated with high BMI.
Methods
Study patients
We performed a retrospective analysis of 202 patients
who attended our Hypertension Clinic and performed
an ICG test for one of the two following clinical criteria:
as part of the initial work-up at the Hypertension Clinic
or follow-up of variations in hemodynamic variables
after adjustments in anti-hypertensive therapy. All the
patients were followed at our department, agreed to per-
form the exam and gave informed consent to participate.
The exam was performed as outpatients and the ICG
exams were not selected based on any time frame. Def-
inition of obesity was based on World Health
Organization criteria (BMI ≥ 30 Kg/m2) and respective
grades: grade 1 with BMI between 30 and 34.9 Kg/m2,
grade 2 with BMI between 35 and 39.9 Kg/m2 and grade
3 with BMI ≥ 40 Kg/m2. The study was approved by the
Ethics Committee of Centro Hospitalar de Lisboa
Central. All patients had been diagnosed with primary
hypertension and no cases of secondary hypertension
were included. All the patients selected had on the day
of the exam AP > 100/60 mmHg under anti-hypertensive
treatment; as we only based in one ICG exam per
patient we excluded the one’s that at the time of the test
were hypotensive, mostly because they might develop
hemodynamic adaptation to lower levels of AP. Uncon-
trolled AP was defined as systolic AP ≥ 140 mmHg and/
or diastolic AP ≥90 mmHg on the day of examination.
Limitations for ICG were also observed and patients
with severe aortic insufficiency, permanent pacemakers,
atrial fibrillation and ventricular extrasystole were not
included in this analysis. Even if the situations of high
BMI may constitute a technical limitation to the ICG
test, we did not exclude patients with grade 3 obesity. In
the literature we can see that the ICG test is not exten-
sively validated in patients whose weight is above 342
pounds [2] (~ 155 kg) due to limitations in signal detec-
tion. Nevertheless, in our cohort the highest weight reg-
istered was 127 kg, a value under the threshold
considered.
On the day of the examination, weight and height data
were collected and the BMI calculated. Blood pressure
was obtained according to the current recommendations
[9] using an oscillometric semiautomatic sphygmoman-
ometer and reported as the average of 2 readings taken
with 2 min intervals. The size of the bladder was ad-
justed to the arm circumference, using a larger bladder
(arm circumference 31–40 cm) in obese patients. Situa-
tions of white coat hypertension could not be completely
excluded because ambulatory blood pressure measure-
ments were not available for all the patients studied.
ICG and determination of hemodynamic variables
ICG, a non-invasive method of hemodynamic monitor-
ing, is based on Ohm’s relationship [10]. It measures the
instantaneous variations of an electrical sign across the
thoracic cavity [2], which are then translated in varia-
tions in blood flow through the great vessels to yield the
effective stroke volume [10]. Because of the differential
properties to conduct current between blood and other
biological tissues like muscle or bone, variations in elec-
trical impedance essentially represent variations in
stroke volume and net content of blood in the thoracic
aorta [2]. Thus, when TFC rise, thoracic impedance falls
since the results of impedance are expressed as the
reciprocal of TFC [11].
All ICG exams were performed by trained technicians
of our Hypertension Clinic and data was obtained during
a scheduled visit. Patients rested for 5 to 10 min before
the procedure and then blood pressure was measured
with the patient in the supine position, with head
elevated at 45 degrees. Then, paired electrodes were
placed in each side of the neck and thoracic cavity [2] to
detect the variations in the electrical sign. The data
obtained (blood pressure values and ICG signals) were
processed and stroke volume calculated.
The remaining variables produced by ICG output were
subsequently analyzed according to a summarized classi-
fication previously published by others [12]:
1. Variables that express cardiac work: stroke volume,
cardiac output, cardiac index and left cardiac work
index
2. Variables that express fluid status: thoracic fluid
content
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3. Variables that express systemic vascular resistance:
systemic vascular resistance and systemic arterial
compliance index
Systemic arterial compliance (SAC) was defined as (10
x supine stroke volume)/ supine pulse pressure and sys-
temic arterial compliance index (SACI) as (10 x supine
cardiac index)/ supine pulse pressure. A SACI < 0.1 sug-
gested arterial stiffness.
Statistics
Considering sample size and distribution of patients
through the different categories of weight classification,
with under-representation of patients with grade 2 and 3
obesity, we performed weight adjustment using SPSS 17
(version 17, Chicago, Illinois). With this statistical ap-
proach we aimed to correct for the lack of representativ-
ity of specific patient groups, namely patients with grade
2 and 3 obesity. Considering also estimates from the
World Health Organization (http://www.euro.who.int/
en/health-topics/noncommunicable-diseases/obesity/
data-and-statistics) for the prevalence of overweight and
obesity for European Union countries of 30–70% and
10–30%, respectively, we saw that in our sample the pro-
portion of overweight (38%) and obesity (37%) was very
similar, not approximating the distribution of BMI in the
population, reason why we performed weight adjustment
of the variable BMI. Statistical analysis presents values
for the different hemodynamic variables for “normal
weight”, “overweight” and “obesity” and also for the
three grades of obesity. T-test was used to compare
“non-obese” (normal weight plus overweight) and “obese
patients” and obese patients with “controlled” and “un-
controlled hypertension” (values of AP ≥140/90 mmHg
on the day of the examination). Finally, using logistic re-
gression analysis analysis and weight-adjusted
hemodynamic variables (CI, LCWI, SVRI and SACI) we
searched for predictors of uncontrolled hypertension in
obese patients. The level of significance was defined to
p < 0.05.
Results
One hundred patients were male (49.5%) and average
age 54.6 ± 13.9 years. Average systolic and diastolic pres-
sures were 136.5 ± 22.4 mmHg and 82.9 ± 5.1 mmHg, re-
spectively. The average BMI was 28.9 ± 5.1 Kg/m2: 46
patients (22.7%) had BMI between 20 and 24.9 Kg/m2,
78 (38.6%) between 25 and 29.9 Kg/m2 and in 75
patients (37.1%) BMI was ≥30 Kg/m2. According to
gender the average values of BMI were 28.5 ± 4.5 Kg/m2
for men and 29.5 ± 5.4 Kg/m2 for women (p < 0.001).
Seventy one patients (35.1%) had systolic AP
≥140 mmHg and 45 patients (22.3%) diastolic AP
≥90 mmHg. BMI correlated with diastolic AP (Pearson’s
coefficient 0.163; p < 0.001) but the association was
stronger for systolic AP (Pearson’s coefficient 0.235; p <
0.001). There was also a positive correlation between
obesity and uncontrolled AP (Pearson’s coefficient 0.138;
p < 0.001), although this correlation was weak.
No adverse effects secondary to the ICG procedure
were reported.
Table 1 presents the values of hemodynamic variables
according to weight categories “normal weight”, “over-
weight” and “obesity” for the cohort studied. Although
no statistical differences were found in CI, LCWI, SVRI
and SACI (p > 0.05) between normal weight and over-
weight patients we observed that differences became
more pronounced with increasing BMI. In this way,
when comparing non-obese (normal and overweight
patients) with obese we observed an increase in CI
(p < 0.001), LCWI (p < 0.001) and SVRI (p < 0.001) but
reduction in SACI (p < 0.001) (Table 2).
However, we also noted that these variations were nei-
ther progressive throughout the 3 grades of obesity nor
statistically significant and, even if we observed an in-
crease in stroke volume and cardiac output with increas-
ing BMI, these changes reflect mainly a greater body
surface area and inherently a physiological larger cardiac
output. Besides, the small number of patients with grade
3 obesity limits the interpretation of these variations
throughout the three grades of obesity (Table 3).
To further characterize AP in obese patients and
hemodynamic factors associated with poor blood
Table 1 Values of hemodynamic variables according to BMI







BMI (Kg/m2) 23.4 ± 1.2 27.3 ± 1.4 34.2 ± 3.6
SAP (mmHg) 133.3 ± 26.6 132.6 ± 19.1 142.9 ± 21.5
DAP (mmHg) 82 ± 13.8 81.6 ± 9.2 85 ± 10.7
CO (L/min) 5.2 ± 1.1 6.5 ± 6.3 6.7 ± 6
CI (L/min/m2) 3.0 ± 0.6 3.0 ± 0.5 3.4 ± 0.6
LCW (Kg.m) 6.6 ± 1.9 6.9 ± 1.6 8.1 ± 2.1
LCWI (Kg.m/m2) 3.9 ± 1.2 3.8 ± 0.8 4.5 ± 4
SV (mL) 80.2 ± 19.3 87 ± 19.6 89.3 ± 23
TFC (/KOhm) 30.3 ± 3.7 30.2 ± 3.7 29.9 ± 3.8
SVR (dyne.sec.cm− 5) 1495 ± 439 1425 ± 490 1361 ± 390
SVRI (dyne.sec.cm− 5.m2) 2514 ± 609 2521 ± 588 2643 ± 706
SAC 17.2 ± 6.1 18.6 ± 6.7 16.5 ± 6.2
SACI 0.65 ± 0.2 0.65 ± 0.2 0.62 ± 0.5
Values of hemodynamic variables presented as average ± standard deviation.
(CI: cardiac index; CO: cardiac output; DAP: diastolic blood pressure; LCW: left
cardiac work; LCWI: left cardiac work index; SAP: systolic arterial pressure; SV:
stroke volume; SVR: systemic vascular resistance; SVRI: systemic vascular
resistance index; TFC: thoracic fluid content; SAC: systemic arterial compliance;
SACI: systemic arterial compliance index)
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pressure control we searched for differences between pa-
tients with controlled and uncontrolled HT (≥140/90
cut-off ) using only weight-adjusted variables. After uni-
variate analysis we found that uncontrolled obese
patients had greater BMI (p < 0.001), CI (p < 0.001) and
SVRI (p < 0.001) (Table 4) but lower SACI (p < 0.001)
and LCWI (p < 0.001). In multivariate analysis (Table 5),
however, only CI remained predictive, conferring a risk
1.47 higher of uncontrolled hypertension. The other
weight adjusted variables (LCWI, SVRI and SACI) were
not associated with increased risk of uncontrolled HT.
Specifically, SVRI, although with statistical significance,
had an odds < 1, suggesting that it doesn’t contribute to
uncontrolled HT in this specific cohort.
Regarding SACI, the odds associated with uncon-
trolled HT was − 1.383, pointing to reduced compliance
as a predictor of difficult to control AP. Besides, SACI
was reduced not only in obese patients with uncon-
trolled HT but also with increasing weight.
Discussion
Obese hypertensives present increased values of CI and
SVRI in comparison with non-obese patients. However,
the most important hemodynamic determinant of
uncontrolled systolic and/or diastolic AP is increased CI.
Taking into account that AP is the product of CO and
SVR, and using weight-adjusted variables, our results
show that in the obese hypertensive patient variations in
CI are more important in determining the level of AP.
In obese patients SAP and DAP were greater than in
non-obese, reflecting that in these patient population
there is increased risk of uncontrolled HT for which







BMI (Kg/m2) 25.8 ± 2.3 34.2 ± 3.6 < 0.001
SAP (mmHg) 132.9 ± 21.8 142.9 ± 21.5 < 0.001
DAP (mmHg) 81.8 ± 10.9 85 ± 10.7 < 0.001
CO (L/min) 6 ± 5.1 6.7 ± 6 < 0.001
CI (L/min/m2) 3.0 ± 0.5 3.5 ± 3.4 < 0.001
LCW (Kg.m) 6.8 ± 1.7 8.1 ± 2.1 < 0.001
LCWI (Kg.m/m2) 3.8 ± 0.9 4.5 ± 4.1 < 0.001
SV (mL) 84.4 ± 19.7 89.3 ± 22.9 < 0.001
TFC (/KOhm) 30.2 ± 3.7 29.5 ± 3.8 0.021
SVR (dyne.sec.cm− 5) 1449 ± 471 1361 ± 389 < 0.001
SVRI (dyne.sec.cm− 5.m2) 2517 ± 590 2643 ± 706 < 0.001
SAC 18.1 ± 6.5 16.5 ± 6.2 < 0.001
SACI 0.65 ± 0.2 0.62 ± 0.5 0.003
Values of the hemodynamic variables presented as average ± standard deviation.
p obtained from T-Test for independent samples. Level of significance defined
to p < 0.05
Table 3 Values of hemodynamic variables from obese patients
according to the degree of obesity






SAP (mmHg) 143.5 ± 21 149 ± 19.5 145 ± 19.6
DAP (mmHg) 85.6 ± 12 86.9 ± 8.2 85.3 ± 6.6
CI (L/min/m2) 3.7 ± 4.6 3.0 ± 0.5 3.4 ± 0.6
LCWI (Kg.m/m2) 4.9 ± 5.5 4.1 ± 1 4.6 ± 0.8
TFC (/KOhm) 29.4 ± 3.4 29.2 ± 4.5 30.6 ± 4.7
SVRI (dyne.sec.cm− 5.m2) 2685 ± 680 2840 ± 830 2298 ± 234
SACI 0.66 ± 0.6 0.52 ± 0.2 0.62 ± 0.2
Table 4 Values of hemodynamic variables from obese patients
with controlled and uncontrolled hypertension





BMI (Kg/m2) 34.1 ± 3.5 35.1 ± 3.9 <
0.001
SAP (mmHg) 127 ± 9.4 157 ± 19.4 <
0.001
DAP (mmHg) 79.1 ± 6.3 90.2 ± 11.1 <
0.001
CO (L/min) 6.2 ± 1.5 7.1 ± 8.1 <
0.001
CI (L/min/m2) 3.1 ± 0.5 3.7 ± 4.7 <
0.001
LCW (Kg.m) 7.6 ± 2.1 8.5 ± 2 <
0.001
LCWI (Kg.m/m2) 4.7 ± 5.8 4.3 ± 1 <
0.001
SV (mL) 93.7 ± 25 84.3 ± 20.1 <
0.001
TFC (/KOhm) 29.7 ± 3.4 29.4 ± 4.2 0.005




2339 ± 467 2915 ± 770 <
0.001
SACI 0.67 ± 0.2 0.59 ± 0.6 <
0.001
Values of the hemodynamic variables presented as average ± standard deviation.
p obtained from T-Test for independent samples. Level of significance defined
to p < 0.05
Table 5 Logistic regression analysis to identify hemodynamic







Constant 0.112 0.005 0.034; 0.190
CI (L/min/m2) 0.210 1.470 < 0.001 0.196; 0.223
LCWI (Kg.m/m2) 0.000 −0.004 0.806 −0.004; 0.003
SVRI
(dyne.sec.cm− 5.m2)
0.000 0.315 < 0.001 0.000; 0.000
SACI −1.452 −1.383 < 0.001 − 1.554; − 1.351
R2 0.392; ANOVA p < 0.001
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seem to contribute both CI and SVRI. There was also
increased LCWI in the obese patients. However, this
variable, which results from the product of mean arterial
pressure and CI, reflects more the higher oxygen
demands of the heart in these circumstances than
increased cardiac performance itself. Probably, this is
also the reason why, in multivariate analysis, LCWI was
not predictive of uncontrolled HT as it relates more with
coronary ischemic threshold and does not represent a
true measure of contractility.
In this way, changes in CI seem to be the most appro-
priate to guide therapeutic adjustments in the hyperten-
sive obese population studied. These results are in
accordance with others previously published [13–16],
where obesity is frequently associated with increased
cardiac output and CI to accomplish with the higher
metabolic demands. In this context, the choice of anti-
hypertensive medication should focus more on drugs like
beta-blockers or central acting agents [3, 7] that may
decrease cardiac output and the effort performed by the
myocardium to pump blood through the vessels.
Concerns about weight gain related to beta-blockers
should be considered, since several trials have docu-
mented an association between beta-blockers, weight gain
and accumulation of visceral adiposity [17, 18]. Central
agonists, to a lesser extent, may be a second choice mainly
due to a more unfavorable profile of side effects.
The SVRI values, with a normal range between 1970
and 2390 dyne.sec.cm− 5.m2, were systematically high
across all groups of patients (normal weight, overweight
and obesity). The differences were significant between
non-obese and obese and became even more pro-
nounced when the cut-off ≥140/90 mmHg was estab-
lished. In this regard, decreasing SVRI, which is an
indirect measure of cardiac afterload, should be part of
the anti-hypertensive regimen using agents like blockers
of the renin-angiotensin-aldosterone system (RAAS) and
calcium channel blockers.
Remarkably, however, SVRI was not predictive of
uncontrolled HT in the obese patient in multivariate ana-
lysis. Although it is expected that vasoconstriction con-
tributes to high levels of blood pressure, several reasons
may explain why we didn’t observe that in our cohort: the
increase in AP levels was not paralleled by the increase in
SVRI and the absence of knowledge on current anti-
hypertensive medication, specially with drugs that inter-
fere with arterial tonus, does not to allow to interpret the
heterogeneity of SVRI values found. However, it is also
recognized that a blunted reduction of peripheral resist-
ance, despite the increased stroke volume and CI, is a
common finding in obesity [14, 16] that may contribute to
the high levels of SVRI observed. Some factors that may
explain this blunted reduction in the tonus of resistance
vessels include activation of the sympathetic nervous
system and release of substances from the adipocytes [1]
leading to high levels of arterial resistance.
Considering SACI, we observed lower levels in the
obese hypertensive, especially in the patients with un-
controlled AP and, in multivariate analysis, this variable
was predictive of uncontrolled AP. Lower levels of SACI,
representing an indirect measure arterial stiffness, were
associated with greater risk of blood pressure ≥ 140/
90 mmHg. Considering that SACI results from the ratio
of CI and pulse pressure it is reasonable to expect, espe-
cially in those with higher levels of blood pressure,
higher values of pulse pressure and, concomitantly,
lower levels of SACI.
It is also worthwhile to note that obese patients, in
general, and those with uncontrolled blood pressure had
lower values of TFC. Although these data do not point
to hypervolemia as a determinant factor to high blood
pressure in this cohort, the absence of data concerning
use of diuretics limits the interpretation of these values.
In the model of multivariate analysis we didn’t included
this variable, as expressed in Kohm and not adjusted to
body surface area, doesn’t reflect volume/m2. Nevertheless,
variations of TFC may be very sensitive and consistent with
volume expansion [19]. The usefulness of TFC
measurements have been previously documented in other
studies, proving beneficial in hypertensive patients to help
guide diuretic adjustments in those who present with
increased chest fluid volume and hypervolemia [19–21]
and also in established heart failure, to identify patients at
risk for acute decompensation [22, 23].
There are limitations to this work since its retrospect-
ive nature and several relevant data missing. One of the
most important in this context concerns information on
current anti-hypertensive medication on the date of the
ICG examination, which we were not able to fully collect
due to technical problems concerning data archives and
lack of data on waist circumference and abdominal obes-
ity. BMI, although reflecting weight excess and being the
basis for obesity grading, does not allow to identify
patients with predominantly central adiposity. The evi-
dence in the literature regarding the pathogenic role of
abdominal fat is vast and the contribution of insulin
resistance, oxidative stress and deregulated synthesis of
hormones by adipose tissue for cardiovascular disease is
well documented [24–28]. In our cohort we observed
high prevalence of overweight and obesity and, probably,
stratifying patients according to values of waist circum-
ference would allow improvement in identifying the
hemodynamic pattern associated with this type of obes-
ity, more frequently associated with HT.
In obese patients, trends in CI and SVRI are clearly
distinct from the one’s we found in lean subjects (which
presented a predominance of increased SVRI in spite of
CI) and it would be important to investigate if central
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obesity is associated with extreme values of the consid-
ered hemodynamic variables or, in alternative, with vari-
ations in other parameters that would impose changes in
anti-hypertensive therapy. It should also be mentioned
that when considering abdominal obesity, in addition to
waist circumference, other elements should also be
taken into consideration, namely the differential com-
position of abdominal fat (subcutaneous versus visceral
fat) and the proportion of fat-free mass. While some
studies support the importance of fat-free mass as a
major determinant of the variations in SV and CO to
accomplish with greater metabolic demands in the obese
patient [14, 29] others suggest the predominant role of
fat mass in the disturbance of hemodynamics [13]. Given
the intense metabolic activity of adipocytes it is expected
that the several molecules they secrete may interfere
with systemic hemodynamic, inducing a state of high CI
and blunted decrease in SVRI. Future research including
a greater number of obese patients, complemented with data
of body composition in terms of relative fat distribution,
would allow for a better understanding of hemodynamic
patterns associated with different types of obesity.
It is also important to refer two other limitations: first,
patients with cardiac arrhythmias were excluded from
this study and, in the general hypertensive population
they represent a large proportion of patients. In this re-
gard, as the study of hemodynamic in this specific subset
is unreliable with ICG, non-invasive determination of CI
and SVRI is compromised in these patients. Second,
when classifying patients with controlled versus uncon-
trolled HT we based exclusively on the values of AP
obtained in the day of examination. Information about
number of medications in each group, time of follow-up
in the Hypertension Clinic or time to achieve blood
pressure control would better describe the differences
between the two groups.
Conclusions
Tailored anti-hypertensive therapy for the obese patient
should focus in the balance between CI and SVRI in each
patient. In our cohort, anti-hypertensive drugs aimed to
modulate cardiac index, mainly beta-blockers, and de-
crease SVRI like inhibitors of the RAAS and calcium
channel blockers seem the most appropriate to control
blood pressure. Increased levels of CI contribute to higher
risk of uncontrolled HT in the obese, situation in which
adjustment of drugs that reduce hyperinotropy may im-
prove and shorten time to blood pressure control.
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